AcuCort targets FDA NDA filing and US launch for Zeqmelit

AcuCort plans to use proceeds from its ongoing rights issue to fund its FDA process for Zeqmelit in the U.S., focusing on preparations for a planned New Drug Application filing and positioning the product for a future U.S. launch.